[ad_1]
(Alliance News) – Evgen Pharma PLC announced on Wednesday that it has started a randomized, placebo-controlled clinical trial of its new SFX-01 tablet.
The Cheshire-based clinical-stage drug developer said it had dosed the first group of volunteers in the 1/1b trial after announcing on Nov. 12.
It said the study aims to provide additional insight into how the drug is absorbed and metabolized in the body, as well as how sulforaphane released by SFX-01 engages key molecular targets related to the disease.
Potential clinical benefits of sulforaphane include the treatment of neurodevelopmental disorders, oncology, and inflammatory conditions.
It is hoped that secreting sulforaphane into a specific part of the intestine will result in a predictable release and reduce gastrointestinal side effects.
“This first dose, on schedule, is an important step in our development plan for SFX-01,” said Chief Executive Officer Hugh Jones, whose results will help Eugene expand into new indications in oncology and neurodevelopmental diseases.
The new SFX-01 enteric-coated tablet formulation replaces its prototype formulation that used hand-filled capsules.
SFX-01 is a patented formulation of synthetic sulforaphane and alpha-cyclodextrin. Eugen has already completed three trials in patients, including a positive open-label trial in metastatic breast cancer.
Shares in Evgen Pharma traded at 5.35 pence in London on Wednesday afternoon.
by Greg Rosenwinge; [email protected]
Copyright 2022 Alliance News Limited. All rights reserved.
[ad_2]
Source link